Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drug

The injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.

Related Keywords

Boston ,Massachusetts ,United States ,Dallas ,Texas ,Carsten Snejbjerg Bloomberg ,Brooke Boyarsky Pratt ,Darren Mcguire ,Steffen Trumpf ,John Sharretts ,Novo Nordisk ,Division Of Diabetes ,Lipid Disorders ,Drug Evaluation ,Getty Images ,Denmark Based Novo Nordisk ,Boyarsky Pratt ,Fox News ,Fox News Digital ,News Digital ,